The concurrent chemoradiation paradigm - General principles

Tanguy Y. Seiwert, Joseph K. Salama, Everett E. Vokes

Research output: Contribution to journalReview articlepeer-review

Abstract

During the past 20 years, the advent of neoadjuvant, primary, and adjuvant concurrent chemoradiotherapy has improved cancer care dramatically. Significant contributions have been made by technological improvements in radiotherapy, as well as by the introduction of novel chemotherapy agents and dosing schedules. This article will review the rationale for the use of concurrent chemoradiotherapy for treating malignancies. The molecular basis and mechanisms of action of combining classic cytotoxic agents (e.g. platinum-containing drugs, taxanes, etc.) and novel agents (e.g. tirapazamine, EGFR inhibitors and other targeted agents) with radiotherapy will be examined. This article is part one of two articles. In the subsequent article, the general principles outlined here will be applied to head and neck cancer, in which the impact of concurrent chemoradiotherapy is particularly evident.

Original languageEnglish (US)
Pages (from-to)86-100
Number of pages15
JournalNature Clinical Practice Oncology
Volume4
Issue number2
DOIs
StatePublished - Feb 1 2007
Externally publishedYes

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'The concurrent chemoradiation paradigm - General principles'. Together they form a unique fingerprint.

Cite this